168 related articles for article (PubMed ID: 37860559)
1. Combinations of plasma cfDNA concentration, integrity and tumor markers are promising biomarkers for early diagnosis of non-small cell lung cancer.
Ren S; Zeng G; Yi Y; Liu L; Tu H; Chai T; Hu L
Heliyon; 2023 Oct; 9(10):e20851. PubMed ID: 37860559
[TBL] [Abstract][Full Text] [Related]
2. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
3. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
4. Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC.
Ren S; Yu C; Huang Q
Lung Cancer Manag; 2024; 13(1):LMT64. PubMed ID: 38812772
[TBL] [Abstract][Full Text] [Related]
5. Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer.
Ezzeldin N; El-Lebedy D; Hassan M; Shalaby AO; Hussein SAM; Gharib AM; Hamdy G; Mohammed AM; Ramadan A; Sobeih ME
J Egypt Natl Canc Inst; 2024 Jun; 36(1):21. PubMed ID: 38880832
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma.
Huang Q; Ji M; Li F; Li Y; Zhou X; Hsueh CY; Zhou L
Mol Cell Probes; 2023 Feb; 67():101895. PubMed ID: 36682577
[TBL] [Abstract][Full Text] [Related]
7. A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA.
Wei L; Wu W; Han L; Yu W; Du Y
Oncol Lett; 2018 Oct; 16(4):4353-4360. PubMed ID: 30250538
[TBL] [Abstract][Full Text] [Related]
8. Analysis of serum cfDNA concentration and integrity before and after surgery in patients with lung cancer.
Fan Y; Shi M; Chen S; Ju G; Chen L; Lu H; Chen J; Zheng S
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):56-63. PubMed ID: 31472048
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.
Kumari S; Husain N; Agarwal A; Neyaz A; Gupta S; Chaturvedi A; Lohani M; Sonkar AA
Pathol Oncol Res; 2019 Jul; 25(3):925-936. PubMed ID: 29376201
[TBL] [Abstract][Full Text] [Related]
10. Integrity and quantity of salivary cell-free DNA as a potential molecular biomarker in oral cancer: A preliminary study.
Rapado-González Ó; López-Cedrún JL; Lago-Lestón RM; Abalo A; Rubin-Roger G; Salgado-Barreira Á; López-López R; Muinelo-Romay L; Suárez-Cunqueiro MM
J Oral Pathol Med; 2022 May; 51(5):429-435. PubMed ID: 35416334
[TBL] [Abstract][Full Text] [Related]
11. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
[TBL] [Abstract][Full Text] [Related]
12. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of cell-free DNA concentration and integrity in serum of gastric cancer patients before and after surgery.
Zhang X; Wu Z; Shen Q; Li R; Jiang X; Wu J; Li D; Wang D; Zou C; Zhong Y; Cheng X
Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):111-117. PubMed ID: 31880527
[TBL] [Abstract][Full Text] [Related]
14. Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma.
Eskander NS; Mansour L; Abdelaal A; Saad E; Mohamed D
Asian Pac J Cancer Prev; 2022 Jan; 23(1):339-348. PubMed ID: 35092403
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice.
González de Aledo-Castillo JM; Arcocha A; Victoria I; Martinez-Puchol AI; Sánchez C; Jares P; Rodríguez GF; Viñolas N; Reyes R; Reguart N; Puig-Butillé JA
J Thorac Dis; 2021 Mar; 13(3):1658-1670. PubMed ID: 33841957
[TBL] [Abstract][Full Text] [Related]
16. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.
Szpechcinski A; Chorostowska-Wynimko J; Struniawski R; Kupis W; Rudzinski P; Langfort R; Puscinska E; Bielen P; Sliwinski P; Orlowski T
Br J Cancer; 2015 Jul; 113(3):476-83. PubMed ID: 26125447
[TBL] [Abstract][Full Text] [Related]
17. Urine cell-free DNA as a promising biomarker for early detection of non-small cell lung cancer.
Ren S; Ren XD; Guo LF; Qu XM; Shang MY; Dai XT; Huang Q
J Clin Lab Anal; 2020 Aug; 34(8):e23321. PubMed ID: 32281142
[TBL] [Abstract][Full Text] [Related]
18. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
19. Application of serum microRNA-9-5p, 21-5p, and 223-3p combined with tumor markers in the diagnosis of non-small-cell lung cancer in Yunnan in southwestern China.
Yang Y; Chen K; Zhou Y; Hu Z; Chen S; Huang Y
Onco Targets Ther; 2018; 11():587-597. PubMed ID: 29430184
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer.
He X; Chi Y; Peng J; Hu W; Ding C; Li B
J Thorac Dis; 2022 Jun; 14(6):2103-2111. PubMed ID: 35813759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
